Navigation Links
Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension

ns. Neither can there be any guarantee that Prexige® (lumiracoxib) will reach any particular level of sales. In particular, management's expectations regarding Prexige® (lumiracoxib) could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the public debate and regulatory activity regarding COX-2 inhibitors like Prexige® (lumiracoxib); unexpected clinical trial results, including additional analysis of existing clinical data and new clinical data; government, industry, and general public pricing pressures; competition in general; Novartis' ability to obtain or maintain patent or other proprietary intellectual property protection; as well as other risk factors discussed in Novartis AG's Form 20-F filed with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Novartis is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

About Novartis Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/15/2014)... HAMILTON, N.J. , Sept. 15, 2014 /PRNewswire-iReach/ ... Bennett , University of South Carolina, submitted a ... FDA Commissioner, asking the FDA to add another ... antibiotic drug labels.  This request asks for a ... events:  "toxic psychoses, hallucinations, paranoia, suicidal thoughts or ...
(Date:9/15/2014)... and BRUSSELS , Sept. 15, 2014 ... UCB (Euronext Brussels:UCB) today announced results from several exploratory ... postmenopausal women with low bone mineral density (BMD). Romosozumab ... work by inhibiting the protein sclerostin, thereby increasing bone ... at the American Society for Bone and Mineral Research ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne ... ambulance transport services, has been selected by Inc. ... companies in America. Photo - ... Inc. 500|5000 list identifies successful, privately-held companies with ... MedicOne Medical Response, one of only two ambulance ...
Breaking Medicine Technology:Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 2Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 2New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 6New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 7New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 8New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 10New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 11New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 12New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 13New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 15MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3
(Date:9/15/2014)... Imaging can be a cost-effective way to ... from aggressive intervention, according to a new modeling study ... study looked at people with asymptomatic carotid artery stenosis, ... to the head due to atherosclerosis, or plaque buildup. ... to 20 percent of ischemic strokes, which result from ...
(Date:9/15/2014)... models, neuroscience researchers at the University of Copenhagen ... that cause Parkinson,s disease. The findings have recently ... Neuroscience . , The defining symptoms of ... shaking. There is currently no cure for the ... research with the potential to shed some light ...
(Date:9/15/2014)... 15, 2014 Today, Zane Benefits, the ... Bank’s Speaking on Business radio show. , According ... so employers know it doesn’t make sense to choose ... also save the employer and employee as much as ... of Zions Bank's Speaking on Business , Chris ...
(Date:9/15/2014)... The Best Hospitals Honor Roll released by ... using OnBase as their enterprise content management (ECM) ... at the top of the list, earning the third ... medical centers across the country with the Honor Roll ... at least six of the sixteen specialties surveyed. ...
(Date:9/15/2014)... U.S. heart experts recommend doctors use a 14-point checklist ... for underlying heart disease that could result in sudden ... American College of Cardiology said in a joint statement ... along with a physical examination can help identify young ... for sudden cardiac death. The statement, published ...
Breaking Medicine News(10 mins):Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 2Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 3Health News:Researchers debunk myth about Parkinson's disease 2Health News:Zane Benefits Featured on Zions Bank Speaking on Business 2Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3
... salt to reduce heart disease risk. The other side says ... people. Which is correct? There isn’t a simple answer. ... component of salt) in the diet lowers blood pressure. But ... her genes, age, and medical conditions, reports the November 2006 ...
... identified a naturally occurring enzyme that can break down ... Alzheimer's disease.// The finding may provide researchers with new ... of Alzheimer's patients and could one day help them ... of Medicine in St. Louis showed earlier this summer ...
... 2007 issue of the Pediatric Blood & Cancer investigates ... healthcare between industrialized and developing countries, as a way ... ,Pediatric oncology has witnessed path breaking strides in ... decades, but developing nations still have a long way ...
... the victims unintentionally demand, or actually have, sex while ... ,Research into this condition called sexsomania has been ... it. This disorder usually causes problems in relationships. It ... ,Several researchers believe sexsomania to be a variant of ...
... to researchers, a gene determines people’s sensitivity to pain.In ... pain could be prevented by blocking the expression of ... This could be a breakthrough in development of new ... a quarter of them had the genetic variant that ...
... of Singapore recently by researchers, reported in the American ... the tangible benefits of curries commonly used by Asian ... meals which are accompanied by a helping of curries ... is often indelibly associated with aging. Asian elders who ...
Cached Medicine News:Health News:Naturally Occurring Enzyme Can Break Down Key Part of Alzheimer's Plaques 2Health News:Videoconferencing, an impetus to Pediatric Oncology 2Health News:Gene determines pain threshold... 2Health News:Spices in curries spruce up aging minds 2
... The SmartDriver System consists of a pistol-grip ... Power, with a wide range of couplers ... of orthopedic surgical applications., ,The Battery ... speed compared to the original Battery SmartDriver. ...
... is an evolutionary product for the inside-out ... designed specifically for use with the Collagen ... becoming a new standard for use in ... a unique method to deliver sutures using ...
... Release System is a technological breakthrough in ... a minimally-invasive approach, provides significant patient benefits. ... of the wrist,creates an entry for the ... a standard video camera system, provides a ...
... a safe alternative to using positive displacement ... such as PCR(a), pipetting radioactive materials and ... excellent for tissue culture, gel loading, serological ... aerosol contaminants and liquids from reaching the ...
Medicine Products: